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Trypanosoma cruzi is the etiological agent of Chagas disease. Following T cell 27 
mediated suppression of the acute phase infection, this intracellular eukaryotic 28 
pathogen persists long-term in a limited sub-set of tissues at extremely low-levels. 29 
The reasons for this tissue-specific chronicity are not understood. Using a dual 30 
bioluminescent:fluorescent reporter strain and highly sensitive tissue imaging that 31 
allows experimental infections to be monitored at single-cell resolution, we have 32 
undertaken a systematic analysis of the immunological micro-environments of rare 33 
parasitized cells in the mouse colon, a key site of persistence. We demonstrate that 34 
incomplete recruitment of T cells to a subset of colonic infection foci permits the 35 
occurrence of repeated cycles of intracellular parasite replication and differentiation 36 
to motile trypomastigotes at a frequency sufficient to perpetuate chronic infections. 37 
The life-long persistence of parasites in this tissue site continues despite the 38 
presence, at a systemic level, of a highly effective T cell response. Overcoming this 39 
low-level dynamic host:parasite equilibrium represents a major challenge for vaccine 40 






KEY WORDS: Trypanosoma cruzi, Chagas disease, chronic persistence, murine 47 


















































INTRODUCTION  51 
The insect-transmitted protozoan parasite Trypanosoma cruzi is the causative agent 52 
of Chagas disease, and infects 5-7 million people in Latin America (1). Despite 53 
decades of effort, only limited progress has been made in developing a vaccine, and 54 
doubts remain about the feasibility of vaccination as a method for disease control 55 
(2,3). In humans, T. cruzi infection passes through an acute stage that lasts 2-8 56 
weeks, during which parasitaemia is readily detectable, although symptoms are 57 
generally mild and non-specific. With the induction of the adaptive immune response, 58 
in which CD8+ IFN-+ T cells play a key role (4,5), there is a significant reduction in 59 
the parasite burden. However, sterile clearance is not achieved and parasites persist 60 
as a chronic life-long infection. One-third of those infected with T. cruzi eventually 61 
develop Chagasic pathology, although symptoms can take decades to become 62 
apparent. Cardiomyopathy is the most common clinical outcome (6-8), followed by 63 
digestive tract dysfunction and megasyndromes, which are reported in about 10% of 64 
infected individuals, often in parallel with cardiac disease.  65 
 66 
Although the innate immune system is able to detect the parasite (9,10), there is a 67 
delay in the subsequent induction of an adaptive response relative to other 68 
pathogens (5,11). This, together with a rapid rate of parasite division (12) and broad 69 
cell type tropism, allows T. cruzi to disseminate widely during the acute stage, with 70 
most organs and tissues becoming highly infected (13). The CD8+ T cell response, 71 
which predominantly targets a sub-set of immunodominant epitopes in members of 72 
the hypervariable trans-sialidase surface antigen family (14,15), is critical for 73 
controlling the acute stage infection in mice, in combination with antibody-mediated 74 
















































disease transitions to a chronic dynamic equilibrium (13). Understanding why the 76 
immune system then fails to eliminate the remaining parasites is a central question in 77 
Chagas disease research. This information is crucial to underpin rational vaccine 78 
design and immunotherapeutic interventions.  79 
 80 
Because of the complexity and long-term nature of Chagas disease in humans, mice 81 
have been important experimental models for research on interactions between 82 
parasite and host. They display a similar infection profile to humans, exhibit chronic 83 
cardiac pathology, and are widely used in drug and vaccine development (16). 84 
Bioluminescence imaging studies have revealed that the GI tract is a major parasite 85 
reservoir during chronic infections and that the degree of containment to this region 86 
is determined by both host and parasite genetics (13,17). Parasites are also 87 
frequently detectable in the skin, and in some mouse models, such as C3H/HeN, 88 
skeletal muscle can be an important site of persistence (4,18). In the colon, the most 89 
frequently infected cells are myocytes located in the gut wall. However, the extent of 90 
infection is low, and in many cases, this entire organ contains only a few hundred 91 
parasites, concentrated in a small number of host cells (18). After transition to the 92 
chronic stage, T. cruzi also exhibits a reduced proliferation rate, although the cycle of 93 
replication, host cell lysis and re-infection appears to continue (12). Evidence for a 94 
form of dormancy in T. cruzi has been reported (19), however whether this is 95 
analogous to dormant/quiescent life-cycle stages observed in other parasites, such 96 
as Toxoplasma gondii bradyzoites and Plasmodium vivax hypnozoites (20), remains 97 

















































Multiple studies have shown that experimental T. cruzi vaccines have protective 100 
efficacy and can reduce both parasitaemia and disease severity (21-26). However, 101 
evidence for complete parasite elimination after challenge, is lacking. In contrast, 102 
drug-cured infections can confer long-lasting protection against re-challenge with a 103 
homologous parasite strain (3), although sterile protection was only achieved in 104 
~50% of animals. Re-challenge with a heterologous strain did not result in sterile 105 
protection, although there was >99% reduction in the peak acute stage parasite 106 
burden. All drug-cured animals that displayed re-infection transitioned to the 107 
canonical chronic stage equilibrium and organ distribution, without passing through 108 
an elevated acute stage parasitaemia. Once established in permissive sites, such as 109 
the GI tract, parasites appear to survive the systemic T. cruzi-specific IFN-+ T cell 110 
response generated by the primary challenge. In the absence of information on the 111 
immunological micro-environment of these persistent parasites, the reasons for this 112 
are unclear. Resolving this question will have a major strategic impact on the 113 
development of an effective vaccine. 114 
 115 
Progress in this area has been limited by technical difficulties in locating and 116 
analysing the rare infection foci in permissive tissue sites, such as the colon. Here, 117 
we describe the application of a T. cruzi bioluminescent:fluorescent dual reporter 118 
strain and enhanced tissue processing and imaging procedures that have allowed us 119 
to show that incomplete homing of leukocytes, including T cells, to foci of intracellular 120 






















































Cellular immunity suppresses the colonic parasite load during chronic T. cruzi 128 
infection. Myocytes in the colonic gut wall are an important site of T. cruzi 129 
persistence in murine models of chronic Chagas disease. However, infected host 130 
cells are extremely rare and unevenly distributed (18), and their immunological 131 
micro-environment has not been systematically investigated. To assess the role of 132 
the immune response in controlling infection at a cellular level in this tissue 133 
compartment, we infected C3H/HeN mice with T. cruzi CL Luc::mNeon, a parasite 134 
line that constitutively expresses a bioluminescent:fluorescent fusion protein (27). 135 
This reporter strain can be used in combination with ex vivo imaging and confocal 136 
microscopy of colonic wall whole mounts to detect infection foci at single cell 137 
resolution (Materials and Methods). When infections had reached the chronic stage 138 
(>100 days post-infection), one cohort of mice was immunosuppressed with 139 
cyclophosphamide, an alkylating agent that is generally suppressive of leukocyte 140 
populations, including both innate cells and T cells (28), and which has been widely 141 
used to drive the reactivation of low-level T. cruzi infections in experimental settings 142 
(29-32). Cyclophosphamide itself has no growth promoting effect on intracellular 143 
amastigotes (Fig. S1). Treatment led to a major reduction in peripheral blood 144 
mononuclear cells (PBMCs) within 5-10 days (Fig. 1a and b; Fig. S2). In parallel, 145 
other groups of mice were subjected to antibody-mediated depletion of the 146 
circulating CD4+ or CD8+ T cell populations (Materials and Methods). This was 147 
achieved, with high specificity, in a similar time-scale (Fig. 1c; Fig. S2). Circulating 148 
















































cyclophosphamide treatment, or by depletion of the CD4+ or CD8+ T cell subtypes 150 
(Fig. 1d).  151 
 152 
Examination of mouse tissue and organs by ex vivo bioluminescence imaging 153 
(13,17) revealed that cyclophosphamide-induced immunosuppression had resulted 154 
in a widespread increase in the intensity of infection (Fig. 2 and 3), including in the 155 
skin, skeletal muscle, GI tract and heart. With CD8+ depletion, skeletal muscle and 156 
the skin were the only tissue sites where we observed a significant enhancement in 157 
the level of infection, with increases of greater than one order of magnitude in some 158 
instances. However, there was a wide variation in the parasite burden between mice 159 
(Fig. 2 and 3), reflecting the dynamic nature of chronic disease infections (13). In the 160 
internal organs, including the GI tract, there was no significant increase in infection 161 
as a result of CD8+ T cell depletion, at least within the time-frame of the experiment. 162 
CD4+ T cell depletion did not promote a relapse in any of the organs or tissue sites 163 
examined (Fig. 2 and 3).  164 
 165 
To further investigate the effect of perturbing the immune system, we undertook 166 
detailed confocal microscopy analysis of external gut walls after removal of the 167 
mucosal layer (Materials and Methods). This technique allows systematic 168 
assessment of the full length and thickness of the longitudinal and circular smooth 169 
muscle layers of the colon at a single cell level (18). Consistent with the ex vivo 170 
imaging data (Fig. 3), this revealed that cyclophosphamide treatment had resulted in 171 
a significant increase in the number of parasite infected cells (Fig. 4). Furthermore, in 172 
the absence of PBMCs (Fig. 1a), it is implicit from the resulting parasite 173 
















































suppression of the infection at this and other sites during the chronic stage (Fig. 2 175 
and 3). However, specific depletion of either the CD4+ or the CD8+ T cell repertoires 176 
(Fig. 1c), by themselves, did not have a significant effect on the number of infected 177 
cells in the colonic gut wall (Fig. 4d).   178 
 179 
Parasites persisting in the colon can induce effective localised T cell 180 
recruitment. At any one time, the majority of the parasite population that persists in 181 
the colon is found in a small number of infected cells that typically contain several 182 
hundred replicating amastigotes, or occasionally, differentiated non-dividing 183 
trypomastigotes (12). The remainder of the population is more widely distributed, 184 
with considerably lower numbers of parasites per infected cell. To better understand 185 
the process of long-term parasite survival, we investigated the cellular micro-186 
environment of persistent infection foci. When infections had advanced to the chronic 187 
stage, peeled colonic wall whole mounts were examined by confocal microscopy 188 
(Materials and Methods), and compared to those of naïve, age-matched control 189 
mice. In the tissue from non-infected mice, using DAPI staining to highlight nuclei, an 190 
average of 55 host cells were identified in 200 m diameter circles positioned around 191 
randomly selected nuclei within the whole mounted gut wall (Fig. 5a). Most cells had 192 
elongated nuclei typical of smooth muscle myocytes. In the infected group, 193 
parasitized cells were identified by green fluorescence (Materials and Methods). 194 
Scanning revealed that total cellularity in the immediate locality of infection foci was 195 
similar in most cases to that in non-infected colonic tissue; the cellularity of 95% of 196 
infection foci was within 3 x S.D. of the background mean, compared with 98% 197 
around randomly selected cells from naïve control regions (Fig. 5a and b). However, 198 
















































infection foci surrounded by a local cellularity that was >4 x S.D. above the 200 
background mean. Within these intense infiltrates, host cells with more rounded 201 
nuclei, typical of lymphocytes, predominated. In contrast to the majority of parasitized 202 
cells that had not triggered a detectable localised response (Fig. 5c), amastigotes in 203 
these inflammatory infiltrates frequently displayed an irregular morphology 204 
suggestive of immune-mediated damage, as judged by the diffuse pattern of green 205 
fluorescence (compare Fig. 5c and d).  206 
 207 
We investigated the nature of these cellular infiltrates, by staining colonic gut wall 208 
whole mounts from chronically infected mice with specific immune cell markers 209 
(Materials and Methods). This revealed, as expected, that leukocytes (identified by 210 
anti-CD45 antibodies) constituted close to 100% of the infiltrate population (Fig. 6a). 211 
A major proportion of the recruited cells were also positive when stained with anti-212 
CD3 antibodies, specific markers for the T-cell receptor complex (Fig. 6b and c), with 213 
both CD4+ and CD8+ T cells represented within this population (Fig. 6d). To assess 214 
the local density of stained immune cells, we examined 200 m diameter circular 215 
tissue sections centred on each infection focus using Z-stack confocal microscopy. A 216 
series of imaged sections starting 5 µm above and 5 µm below the centre of the 217 
parasite nest (a total volume of 314 m3) were generated, and the number of stained 218 
cells in the infection micro-environment determined in 3-dimensions (Fig. S3). In 219 
sections of colonic smooth muscle from non-infected mice, leukocytes were 220 
dispersed and rare, with an average of ~1 CD45+ cell per 314 m3, although they 221 
were more numerous in the sub-mucosal tissue (Fig. S4). Using a cut-off value of 3 x 222 
S.D. above the respective background level, 40 - 45% of infection foci displayed 223 
















































persistence, dynamic homing of leukocytes, including T cells, to parasitized cells in 225 
the murine colon is a characteristic of chronic stage infection, although at any one 226 
point in time, not all parasite nests will have triggered this type of recruitment 227 
response. Given the ‘snapshot’ nature of imaging, our data therefore suggest that in 228 
the majority of cases, a likely outcome of colonic cell invasion will be infiltration of 229 
leukocytes prior to completion of the T. cruzi intracellular cycle, and the presumptive 230 
destruction of the parasites (Fig. 5d). 231 
 232 
Incomplete homing of protective T cells allows a subset of intracellular colonic 233 
infections to complete their replication cycle. Evidence indicates that T. cruzi 234 
rarely occupies individual colonic myocytes for extended periods (>2 weeks) (12), 235 
suggesting that parasites are either efficiently eliminated by the immune response, or 236 
that they complete a cycle of replication, trypomastigogenesis and host cell lysis 237 
within this period. In addition, there is considerable variation in the level of infection 238 
within individual colonic cells at any one time, with parasite numbers that can range 239 
from 1 to >1000 (12). We therefore investigated whether the immune response 240 
induced against infected cells increased in line with the intra-cellular parasite burden. 241 
When the levels of infiltrating leukocytes in the local environment of infected cells 242 
were compared with the number of intracellular T. cruzi parasites, we found no 243 
apparent correlation (Fig. 7a, b and c). This was the case irrespective of whether 244 
anti-CD45, anti-CD4 or anti-CD8 antibodies were used to assess the nature of the 245 
cellular infiltrate. It is implicit therefore, that the elapsed duration of an individual 246 
intracellular infection, as inferred from the extent of parasite proliferation, is not a 247 

















































Of 237 infected colonic cells detected in 13 animals, only 4 (~1.7%) contained 250 
parasites that had clearly differentiated into flagellated trypomastigotes, the life-cycle 251 
stage that disseminates the infection by re-invasion of other host cells, or via 252 
transmission to the blood-sucking triatomine insect vector. Of these, three contained 253 
large numbers of parasites (>1,000), while the fourth contained 128. In each case, 254 
the leukocyte densities in the local micro-environment were within a range similar to 255 
host cells where the infection was less mature, as judged by the number of 256 
intracellular amastigotes and their lack of differentiation into trypomastigotes. In the 257 
example shown (Fig. 8a and b), Z-stack imaging was used to serially section a large 258 
nest containing >1,000 parasites, and shows mature trypomastigotes in the act of 259 
egress, despite the recruitment of a small number of CD45+ leukocytes, including 260 
CD8+ T cells (Fig. 8c and d). Therefore, for a small proportion of infected cells, 261 
including in some cases large and mature parasite pseudocysts, the host immune 262 
system is either not triggered locally by an infection, is too slow to respond, or is in 263 
some way suppressed. As a result, in the colon, it is possible for the entire cycle of 264 
parasite proliferation, differentiation and egress to occur in the absence of effective 265 
intervention by a cellular immune response, at a level sufficient to allow prolongation 266 
of the chronic infection.    267 





























































Discussion    282 
Despite the generation of a vigorous and specific CD8+ T cell response (4,14,33,34), 283 
T. cruzi infections in mice are rarely cleared to sterility, even in vaccinated animals. 284 
Instead, parasites persist predominantly in a small number of reservoir tissue sites, 285 
typically for the life-time of the host (10). One possibility is that intermittent 286 
dissemination from these locations to less permissive organs, which include the 287 
heart, could promote repeated episodes of infection, resulting in localised 288 
inflammatory responses that contribute to disease pathology in a cumulative manner 289 
(35). Understanding why the immune system efficiently suppresses, but fails to 290 
eliminate T. cruzi infections, is one of the key challenges in Chagas disease 291 
research. Here, using tissue processing techniques that allow the immunological 292 
micro-environment of infection sites in the colon to be assessed at single cell 293 
resolution, we demonstrate that CD45+ leukocytes, including both CD4+ and CD8+ T 294 
cells, are frequently recruited to chronic infection foci within a reservoir tissue. 295 
However, for a small sub-set of infected cells, effector cell recruitment is either 296 
absent, or too slow to prevent completion of the intracellular cycle of parasite 297 
proliferation and differentiation to the motile trypomastigote stage (Fig. 8). Thus, 298 
chronic T. cruzi infections in the colon are not characterised by a generalised tissue-299 

















































T cell recruitment during T. cruzi infection is driven by secretion of chemokines from 302 
infected cells. For example, the CXCR3 ligands CXCL9 and CXCL10 have been 303 
implicated in cardiac infiltration (36). IFN-and TNF- expression by antigen specific 304 
CD8+ T cells (4), and subsequent iNOS expression (37-39), potentially from recruited 305 
innate monocytes/macrophages or from somatic cells of the infected tissue, then 306 
increases the local concentration of reactive nitrogen species. In Chagas disease, 307 
the resulting inflammatory environment tightly controls the number of infected cells, 308 
but can also act as the key driver of chronic immunopathology (7,14,40,41). An 309 
important observation from our study is that the likelihood of T cell recruitment in the 310 
colon is not linked with the maturity of individual T. cruzi nests, as judged by the 311 
intracellular parasite load (Fig. 7). As a result, in some parasitized cells, 312 
differentiation to the flagellated trypomastigote form can occur without inducing 313 
infiltration of leukocytes in sufficient time to block a productive infection (Fig. 8). 314 
 315 
The reasons why protective T cells are not recruited to a small sub-set of infection 316 
foci are unclear. Hypothesised mechanisms to account for T. cruzi immune evasion 317 
include a general absence of pathogen associated molecular patterns (PAMPs) (42), 318 
cytokine-mediated inhibition of effector responses (10), insufficiently strong 319 
chemoattractant signalling in low parasite load settings (40), the extensive antigenic 320 
diversity expressed by the large families of trans-sialidase and mucin genes 321 
(14,43,44), and stress-induced cell-cycle arrest and dormancy (19). However, none 322 
of these obviously correspond with our observation that there is an apparent lack of 323 
association between the extent or longevity of an individual cellular infection and the 324 
magnitude of localised leukocyte recruitment (Fig. 7). Some highly infected host cells 325 
















































trigger massive cellular infiltration. One explanation could be that a slow-down in the 327 
intracellular amastigote replication rate during chronic stage infections (12) 328 
contributes to reduced immune detection. In circumstances where the infected cell is 329 
in an area of the colon that is otherwise parasite-free, this may be sufficient to permit 330 
completion of the initial replication cycle. However, after trypomastigote egress and 331 
host cell lysis, the resulting tissue disruption and production of damage associated 332 
molecular patterns (DAMPs) could act to enhance leukocyte recruitment into the 333 
area, leading to the destruction of parasites that have re-invaded host cells in the 334 
vicinity of the initial infection. In contrast, trypomastigotes which migrate further from 335 
this DAMP-enriched locality may be able to establish a productive infection in the 336 
absence of rapid immune detection. Despite a diverse and complex antigenic 337 
repertoire, induction of the T cell response in draining lymph nodes is known to be 338 
highly focussed (14), and once T cell recruitment has been triggered, parasite 339 
destruction can be initiated (Fig. 5d). Widespread parasite dormancy was not evident 340 
in the colon (12), and does not appear to be necessary for immune evasion in this 341 
tissue site.  342 
 343 
Success or failure of the immune system in eliminating these rare chronic infection 344 
foci may be a largely stochastic process resulting from the dynamic interplay 345 
between the host and pathogen at a single cell or tissue micro-domain level. If 346 
parasites were able to universally suppress innate detection pathways, with 347 
concomitant reduction in localised chemokine output, this would have a negative 348 
impact on host survival, and thus long-term T. cruzi transmission. Conversely, if 349 
nests were always detected by the immune system before completion of the 350 
















































to persist in some organs/tissues, may therefore be dependent on the propensity, or 352 
otherwise, of these tissues to amplify the chemokine signals triggered by low-level 353 
infection, with a possible role for closely adjacent re-infections in the amplification 354 
process. In mice, there are strain-specific differences in the extent of such tissue-355 
restriction during chronic infections. This could have parallels in humans, and 356 
account for the heterogeneous profile of disease progression.    357 
 364 
T. cruzi infection induces a high titre polyclonal B cell/antibody response during the 365 
acute stage of infection, which although delayed and initially unfocussed (45), does 366 
contribute to parasite control and can protect against virulent infections. In the 367 
chronic stage, a role for the humoral response in suppressing the dissemination of 368 
persistent parasites is unresolved (10), and a key role for B cells has not been 369 
identified. Here, we show that in the absence of PBMCs, circulating antibodies, 370 
which in the short-term are not profoundly affected by cyclophosphamide treatment 371 
(46) (Fig. 1d), are unable to compensate for T cell depletion and maintain tissue-372 
specific repression of the parasite burden (Fig. 2 and 4d). If the humoral response 373 
does have a significant protective role during the chronic stage, for example, 374 
involving opsonisation of the parasite through FcR-antibody binding, then this 375 
function could be lost on depletion of key cellular effectors. In addition, our results do 376 
not exclude the possibility that parasite-specific antibodies could act to limit 377 
infections at a systemic level, over a longer duration, perhaps by controlling 378 
trypomastigote numbers or restricting their spatial dissemination.  379 
 380 
The central role of CD8+ T cells in suppressing T. cruzi infections is well established, 381 
















































cells leads to partial recrudescence in specific organs (4,5,15,34). In the 383 
experimental model outlined here, this relapse took place in skeletal muscle and skin 384 
(Fig. 2 and 3), although had the period of CD8+ depletion been extended, we cannot 385 
exclude the possibility that relapse, as inferred from the bioluminescence signal, 386 
would also have been identified at other sites. When we examined the effect of CD8+ 387 
T cell depletion at a cellular level in the colon, where tissue processing procedures 388 
allow systematic analysis, we found no significant increase in the number of infected 389 
cells, in contrast to the major rebound observed with cyclophosphamide-mediated 390 
reduction of the entire PBMC population (Fig. 1-4). Whether this was a result of less 391 
efficient depletion of CD8+ T cells at this site, or that the protective role is better 392 
covered by CD4+ T cells or innate populations, will be an important question to 393 
address. A non-redundant function for CD4+ T cells is less well established in murine 394 
models of Chagas disease (47-49), although in humans with untreated HIV co-395 
infections, parasites become easily detectable in the bloodstream and can result in 396 
CNS pathology (50). Since depletion of either CD4+ or CD8+ T cells by themselves 397 
did not promote the level of systemic relapse observed with cyclophosphamide 398 
treatment over the time period analysed (Fig. 2 and 3), our results therefore suggest 399 
that either both lymphocyte sub-types are able to contribute to suppression of 400 
chronic stage infections in the colon, or that innate monocytes/macrophages are able 401 
to provide a covering role during this time-period. The further development of tissue 402 
processing and imaging procedures applicable to other organs and tissues, to allow 403 
systematic analysis of chronic infections at single cell resolution, will be an important 404 

















































If our findings in experimental mice are translatable to humans, this will have 407 
important implications for anti-T. cruzi vaccine development. Vaccines protect by 408 
presenting non-tolerised antigens in the correct immunological context, to expand 409 
small numbers of antigen-specific naïve T and B cells, which then generate a sub-410 
population of memory cells. The expanded memory populations then allow more 411 
rapid deployment of adaptive effectors on future contact with the pathogen. 412 
However, T. cruzi is able to persist indefinitely in hosts that already have expansive 413 
systemic populations of effective T cells. Unless vaccines can prevent parasites from 414 
accessing permissive sites after the initial infection, or they are able to enhance 415 
successful homing of adaptive effector cells, it will be difficult to achieve sterilising 416 
immunity. Drug-cured infections can confer complete protection against re-challenge 417 
with a homologous strain, but with heterologous strains, despite the prevention of an 418 
acute stage peak, the infection proceeds directly to a status that is analogous to the 419 
chronic stage in terms of parasite burden and tissue distribution (3). Therefore, it is 420 
likely that successful anti-T. cruzi vaccines will require an ability to eliminate 421 
parasites at the initial site of infection during the first intracellular replication cycle. 422 






























































Materials and Methods 438 
Mice and parasites. All experiments were performed using female C3H/HeN mice, 439 
purchased from Charles River (UK). They were maintained in individually ventilated 440 
cages, under specific pathogen-free conditions, with a 12-hour light/dark cycle, and 441 
provided with food and water ad libitum. Research was carried out under UK Home 442 
Office project licenses PPL 70/8207 and P9AEE04E4, with approval of the LSHTM 443 
Animal Welfare and Ethical Review Board, and in accordance with the UK Animals 444 
(Scientific Procedures) Act 1986 (ASPA). The T. cruzi line CL Luc::mNeon, a 445 
derivative of the CL Brener strain (discrete typing unit TcVI), was used in all 446 
experiments. It had been genetically modified to express a 447 
bioluminescent:fluorescent fusion protein containing red-shifted luciferase and 448 
mNeonGreen fluorescent domains (27,51). For infections, C3H/HeN mice, aged 6-8 449 
weeks, were inoculated i.p. with 1x103 bloodstream trypomastigotes obtained from 450 
immunodeficient CB17-SCID mice, as described previously (30). Mice were then 451 
monitored by in vivo bioluminescence imaging (17) which indicated that they had 452 
transitioned to the chronic stage by 50-60 days post-infection. Experiments were 453 

















































Suppression of the murine immune response. General immunosuppression was 456 
achieved by injecting mice i.p. with cyclophosphamide (200 mg/kg) at 4-day 457 
intervals, up to a maximum of 3 injections, in accordance with animal welfare 458 
(17,30). Circulating CD8+ T cells were depleted by i.p. injection of 400 g of the YTS 459 
169.4 monoclonal anti-CD8 (2BScientific), diluted in PBS, at 4-day intervals, up to a 460 
maximum of 4 times (Fig. 1C). The same regimen was applied for depletion of CD4+ 461 
T cells, using the GK1.5 monoclonal antibody (2BScientific).  462 
 463 
Tissue processing and imaging. When mice were sacrificed, organs and tissues 464 
were removed and transferred to a Petri dish in a standardized arrangement, soaked 465 
in 0.3 mg/ml d-luciferin in PBS, and examined by ex vivo bioluminescence imaging 466 
using the IVIS Spectrum system (Caliper Life Science) and the LivingImage 4.7.2 467 
software (52). The skin was removed from the carcass, and following subcutaneous 468 
adipose tissue removal, was placed fur down, soaked in 0.3 mg/ml d-luciferin and 469 
imaged under the same conditions as the internal organs. The carcass was placed 470 
dorsal side up, soaked in 0.3 mg/ml d-luciferin, and imaged as above. 471 
 472 
Colonic muscularis walls were isolated by peeling away the mucosa, whole mounted 473 
as described previously (18), and then exhaustively searched for parasites (green 474 
fluorescence) with a Zeiss LSM880 confocal microscope. Small tissue sections (~5 475 
mm2) around parasite nests were excised from the whole mount by scalpel, washed 476 
twice in PBS and incubated for 2 days in 1:300 primary antibody diluted in PBS / 5% 477 
fetal calf serum / 1% Triton-X100 at 4oC. Following 2 further washes in PBS, 478 
















































added to the tissue sections, and incubated for 3 hours at room temperature. 480 
Sections were then mounted in Vectashield, containing the DNA stain DAPI, and 481 
imaged by confocal microscopy. Colonic muscularis walls from naïve aged-matched 482 
mice were similarly prepared as controls, with and without the primary antibody.  483 
 484 
For accurate determination of intracellular parasite and surrounding host cell 485 
numbers, tissue samples were imaged in 3-dimensions (Z-stacking), with the 486 
appropriate scan zoom setting (18). The Image Browser overlay function was used 487 
to add scale bars, and images were exported as .TIF files to generate figures. 488 
Primary antibodies used were as follows: anti-luciferase (G7451, Promega), CD45 489 
(Tonbo Biosciences, 30-F11), CD3 (Abcam, ab11089), CD4 (Abcam, ab25475), CD8 490 
(Abcam, ab25478). The secondary antibodies were Invitrogen A-11055, Invitrogen 491 
A-21434, Invitrogen A-11007.  492 
 493 
Flow cytometry. At each time-point, mice were placed in a “hot box” and left at 38oC 494 
for 10 minutes. They were then placed in a restrainer and the lateral tail vein 495 
punctured using a 0.5M EDTA (pH 7.4) soaked 21G needle. A single drop of blood 496 
was transferred to a 2 ml tube and 10μl 0.5M EDTA added to prevent clotting. Each 497 
sample was then mixed with 400 l ice-cold PBS and placed onto 300 l Histopaque 498 
1083 (Sigma-Aldrich), and spun at 400 g for 30 minutes in a microcentrifuge. The 499 
monocytic layer was aspirated using a pipette, mixed with 1 ml ice-cold PBS, 500 
pelleted and resuspended in 200 l flow cytometry buffer (PBS, 5% fetal bovine 501 
serum, 0.05% sodium azide), and 1 l of the cocktail of conjugated antibodies added 502 
(1:200 dilution in each case). After 1 hour incubation in the dark, cells were pelleted 503 
















































incubation in the dark. The stained fixed cells were then pelleted, re-suspended in 505 
filtered flow cytometry buffer and transferred to standard flow cytometry tubes. 506 
Samples were analysed using a BD Bioscience LSRII flow cytometer, with plots 507 
created and analysed in FlowJo V.10.6.1. The following antibodies were used: CD45 508 
(ThermoFisher, 30-F11, Super Bright 600), CD3 (ThermoFisher, 17A2, FITC), CD4 509 
(ThermoFisher, RM4-5, eFluor 450), and CD8 (ThermoFisher, SK1, Alexa Fluor 510 
780). 511 
 512 
α-T. cruzi antibody ELISA. 96-well plates were coated with sonicated T. cruzi CL 513 
Luc::mNeon trypomastigote lysate; 100 l (0.5 g) per well diluted in 15 mM Na2CO3, 514 
34.8 mM NaHCO3. The plates were incubated at 4oC overnight to allow antigen 515 
binding, washed 3x with PBS / 0.05% Tween 20, and then blocked with PBS / 2% 516 
milk powder. Diluted murine serum samples, collected from each Histopaque 517 
separation, were further diluted to 1:1600. These were aliquoted in triplicate (100 l 518 
per well) and incubated for 1 hour at 37oC. Horse radish peroxidase (HRP) 519 
conjugated anti-mouse IgG secondary antibody (Abcam, ab99774) was then added 520 
(1:5000; 100 l per well), and the plates incubated for a further 1 hour. After the 521 
addition of HRP substrate (80 l per well) (Stabilised TMB, Life Technologies), the 522 
plates were incubated at room temperature in the dark for 5 minutes and read using 523 
a FLUOstar Omega plate reader (BMG LABTECH), after the addition of 40 l 1M 524 
HCl. 525 
 526 
Testing for the effect of cyclophosphamide on T. cruzi growth. A 96-well plate 527 
was seeded with 5000 MA104 cells/well, and 18 hours later these were infected with 528 
















































was allowed to occur overnight, the wells were washed thoroughly with serum-free 530 
medium, and intracellular amastigotes allowed to proliferate for 24 hours. 531 
Cyclophosphamide was then added up to a concentration of 200 μM.  3 days later, 532 
the intensity of green fluorescence was recorded on a FLUOstar Omega plate 533 
reader, and the impact on parasite growth assessed. 534 
 535 
Statistics. Analyses were performed in GraphPad PRISM v8.0. S.D. Fold change in 536 
bioluminescence intensity was compared using a one-way ANOVA with Dunnett’s 537 
pairwise comparisons. Background cellularity and CD45+, CD4+ and CD8+ cut-offs 538 
were set as mean + 3 x S.D. Data sets were compared using a 2-sample t-test with 539 
Welch correction. If data were not normally distributed, as assessed using a Shapiro-540 
Wilk test, a Mann-Whitney rank sum test was used.  541 
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FIG 1  Suppression of cellular immunity in mice chronically infected with T. cruzi. (a) 738 
C3H/HeN mice chronically infected (>100 days) with T. cruzi CL Luc::mNeon (n=6) 739 
were immunosuppressed by i.p. inoculation with cyclophosphamide (200 mg/kg) at 740 
4-day intervals, up to a maximum of 3 injections (Materials and Methods). The % 741 
events recorded as peripheral blood mononuclear cells (PBMCs) at different time 742 
points after the initiation of treatment for individual mice are shown. Also included in 743 
the day 1 values are additional data points (n=24) from immunocompetent 744 
chronically infected mice. (b) Flow cytometry plots showing the loss of detectable 745 
events in the PBMC gate (black oval) over the course of cyclophosphamide 746 
















































(FFC, Y-axis) and side (SSC, X-axis) scatter. (c) Effective depletion of T cell subsets 748 
by treatment of mice with specific anti-CD4 or anti-CD8 antibodies (Materials and 749 
Methods). The graphs show the CD4+ and CD8+ flow cytometry events of individual 750 
mice as a % of the total CD3+ population over the treatment periods. (d) ELISA mean 751 
absorbance readings (using anti-mouse IgG secondary antibody) for serum from 752 
chronically infected mice that had been treated with cyclophosphamide, or treated 753 
with anti-CD4 or anti-CD8 antibodies. Microtitre plates containing T. cruzi 754 
trypomastigote lysates were prepared as described (Materials and Methods). 755 
Dashed red lines identify the mean, +1 x S.D. and +2 x S.D. values, determined from 756 
immunocompetent chronic stage controls (n=28). One of the anti-CD8 antibody 757 
treated mice died between day 5 and 9, and was excluded from subsequent 758 
analysis. 759 
 760 
FIG 2  Fold change in radiance (p/s/cm2/sr) established by ex vivo bioluminescence 761 
imaging of internal tissues and organs from C3H/HeN mice chronically infected with 762 
T. cruzi (control), and after treatment with cyclophosphamide, anti-CD4 or anti-CD8 763 
antibodies, as indicated (Materials and Methods). Infection intensities were 764 
determined using LivingImage software to draw individual regions of interest around 765 
each organ and tissue sample (17). Data from infected mice were normalised to 766 
account for variations in background radiances of different tissue types by using 767 
matching tissues from uninfected controls to establish the fold change. The maximal 768 
value from the uninfected organs was used. The dashed line indicates the detection 769 
threshold, equal to the mean +2 SDs of the bioluminescence background derived 770 
from the fold change between empty regions of interest in tissue from age-matched 771 
















































points also include values from additional immunocompetent chronically infected 773 
mice (n=17) (18). Means are compared with a one-way ANOVA with post hoc 774 
Dunnett’s pairwise comparisons test; * = p<0.05, ** = p<0.01, *** = p<0.001. 775 
 776 
 777 
FIG 3 Tissue-specific impact of T cell depletion on parasite burden. C3H/HeN mice 778 
chronically infected with T. cruzi CL Luc::mNeon were treated with 779 
cyclophosphamide, anti-CD4 or anti-CD8 antibodies as outlined in the legend to Fig. 780 
1. 16 days post-treatment initiation, organs and tissues were examined by ex vivo 781 
imaging (52) (Materials and Methods). (a) Representative bioluminescence images 782 
of internal organs from treated mice arranged as shown in the inset (left). (b) Dorsal 783 
bioluminescence images following removal of internal organs, fur, skin and major 784 
adipose depots (Material and Methods). (c) Ex vivo bioluminescence imaging of skin 785 
(adipose tissue removed). Radiance (p/s/cm2/sr) is on a linear-scale pseudo-colour 786 
heat map. The heat map image of skeletal bioluminescence after treatment with anti-787 
CD8 antibodies is shown at an increased minimum and maximum radiance (1x104 – 788 
1x106) to avoid saturation of the image. The complete radiance data set is shown in 789 
Fig. 2. 790 
 791 
 792 
FIG 4  Control of parasites in the colon of chronically infected mice is lost on 793 
suppression of cellular immunity. (a) Colon sections from C3H/HeN mice chronically 794 
infected with T. cruzi CL-Luc::mNeon were pinned luminal side up and examined by 795 
ex vivo bioluminescence imaging. Radiance (p/s/cm2/sr) is on a linear-scale pseudo-796 
















































inset, section from mice immunosuppressed by cyclophosphamide treatment 798 
(Materials and Methods). (b) Schematic highlighting the distinct layers of the GI tract. 799 
The dashed red line and arrow indicate the position above which tissue can be 800 
peeled off to leave the external colonic wall layers (18). (c) External gut wall whole 801 
mounts were examined in their entirety at a 3-dimensional level by confocal 802 
microscopy. Examples of parasite infected cells in immunocompetent mice and their 803 
locations, detected by green fluorescence (mNeon). DAPI staining (blue) identifies 804 
host cell nuclei. Scale bars=20 m. (d) The total number of parasitized cells counted 805 
in each whole mounted colonic gut wall for the control and the immune-depleted 806 
groups. Each dot represents a single mouse, with the colons examined 12-22 days 807 
post treatment initiation (see Fig. 1d). **** = p≤0.0001. Differences between control 808 
values and those obtained from mice that had been treated with anti-CD4 and anti-809 
CD8 antibodies were non-significant.  810 
 811 
 812 
FIG 5  Defining the localised cellularity of T. cruzi infected host cells in the colonic 813 
gut wall. (a) Images of whole mounted colonic gut wall from C3H/HeN mice 814 
chronically infected with T. cruzi CL-Luc::mNeon (Materials and Methods). When 815 
infection foci were identified, 200 m diameter circles were drawn centred on each 816 
parasite cluster or ‘nest’. Circles were placed by centring on randomly selected cells 817 
in the case of non-infected age-matched controls (top left panel). DAPI-stained 818 
nuclei (blue) that fell within this disc (highlighted by white dots) were counted as a 819 
measure of cellularity. Intracellular parasites can be identified by green fluorescence. 820 
These are indicated by white arrows in the lower images. (b) Background cellularity 821 
















































naïve age-matched C3H/HeN mice was established as above. With tissue from 823 
chronically infected mice, localised cellularity was calculated using circles centred on 824 
parasite foci (green) (n=247). Individual values are indicated by blue (non-infected) 825 
and green (infected) dots. The dashed lines indicate 3 x S.D. and 4 x S.D. above the 826 
background mean. (c) An infected myocyte where the local cellularity is equivalent to 827 
the background level and the intracellular amastigotes (green) are structurally intact. 828 
(d) Zoomed-in image of an intense cellular infiltrate (nuclei, blue) in which the T. 829 
cruzi parasites (green) display an irregular and diffuse morphology. Parasite DNA is 830 
identifiable as small discrete DAPI-stained spheres throughout this inflammatory 831 
focus (examples indicated by white arrows). Scale bars=20 m.  832 
          833 
               834 
FIG 6  T cells are major constituents of the leukocyte population recruited to chronic 835 
stage infection foci. (a) Confocal images of colonic gut wall sections from chronically 836 
infected mice (Materials and Methods). Rare infection foci were identified by 837 
mNeonGreen fluorescence (parasites) after exhaustive searching of whole mounted 838 
gut walls. Staining with anti-CD45 (orange) reveals that hematopoietic cells 839 
constitute the vast majority of the infiltrate population. Host cell nuclei were identified 840 
by DAPI staining (blue). (b) Anti-CD3 staining of cellular infiltrates shows that T cells 841 
constitute a majority of the population. Blue, host cell nuclei; red, CD3 staining; 842 
green, parasite fluorescence. (c) Serial Z-stack imaging (Materials and Methods) 843 
through the same cellular infiltrate as in b, showing selected sections through the 844 
infiltrate. (d) Histological sections containing cellular infiltrates and associated 845 
infection foci (parasites, green; indicated by white arrows in right-hand image) 846 
















































m. (e) Whole mounts containing infection foci were stained with anti-CD45, anti-848 
CD4, or anti-CD8 antibodies and the number of positive host cells in the immediate 849 
vicinity (314 m3 volume) was determined by serial Z-stack confocal imaging. Each 850 
dot corresponds to a single infection focus. The horizontal dashed line is 3 x above 851 
the S.D. of the mean background level in non-infected tissue. In the case of anti-852 
CD45 staining, none of the 50 tissue regions examined from non-infected mice 853 
contained CD45+ve positive cell numbers above this value. 41%, 45% and 42% of 854 
infection foci identified by CD45, CD4 and CD8 staining, respectively, were above 855 
this cut-off.  856 
 857 
 858 
FIG 7  Lack of correlation between intracellular parasite load and localised T cell 859 
infiltration during chronic infections. (a) Comparison of the parasite numbers in 860 
infected colonic gut wall cells with the local leukocyte cell density. Infection foci were 861 
identified in whole mounts of colonic tissue, which were then stained with anti-CD45 862 
antibody (Materials and Methods). The parasite and cell numbers in a tissue volume 863 
of 314 m3 were determined using serial Z-stack imaging, with leukocytes identified 864 
by orange staining and parasites by green fluorescence.  The horizontal dashed line 865 
is 3 x above the S.D. of the mean background level in non-infected tissue. Each dot 866 
identifies a single infection focus, with tissue samples derived from 6 mice (71 867 
infection foci). The confocal images show representative infection foci used to 868 
generate the data, and illustrate the varying extents of leukocyte infiltration. (b) 869 
Similar analysis of infection foci using anti-CD4 staining (purple). Tissue samples 870 
were derived from 3 mice (54 infection foci). (c) Analysis of infection foci using anti-871 


















































FIG 8  Incomplete recruitment of leukocytes to parasite nests allows progression of 875 
T. cruzi through the full intracellular infection cycle. (a) An intense bioluminescent 876 
focus in a chronic stage distal colon viewed by ex vivo imaging (Materials and 877 
Methods). Radiance (p/s/cm2/sr) is on a linear-scale pseudocolour heatmap. (b) 878 
Confocal imaging of the corresponding parasite nest showing representative serial Z-879 
stack images taken along the depth of the infected cell. The Z-axis position relative 880 
to the centre of the nest is indicated above each of the images. Parasite numbers 881 
(>1000) were established from green fluorescence and the characteristic DAPI 882 
staining of the parasite kinetoplast DNA (the mitochondrial genome) (18) (blue). 883 
Infiltrating leukocytes (orange) were identified by staining with anti-CD45 antibodies 884 
(Materials and Methods). Scale bar=20 m. (c) Enlarged images of a small cluster of 885 
infiltrating CD45+ (orange) and CD8+ (yellow) cells in close vicinity to the nest. White 886 
arrows indicate leukocytes corresponding to CD8+ T cells. (d) Egress of 887 
differentiated trypomastigotes into the extracellular environment. Data from the 888 
infected cell captured in these images was not included in Fig. 7 since the parasite 889 
burden was too great to determine numbers with precision. 890 
 891 
 892 
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